http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-2.xsd
A comparative study of ondansetron versus metoclopramide in the prevention of post operative nausea and vomiting in routine major gynecological surgery under general anesthesia
ABSTRACT: A comparative study of ondansetron versus metoclopramide in the prevention of post-operative nausea and vomiting in routine major gynecological surgery under anesthesia. Objective: The purpose of this study was to perform a comparative study of injection ondansetron 8 mg I.V. with injection metoclopramide 10mg I.V. in preventing post-operative nausea and vomiting. Design: this was a randomized, double blinded study conducted in sixty patients of ASA I and ASA II undergoing routine major gynecological surgery (TAH, laprotomy and cystectomy, tubal surgery) under general anesthesia in the Maternity Hospital, Thapathali, Kathmandu. Methods : Either of the drug was diluted to 10 ml of normal saline and given intravenously prior to induction of anesthesia. The whole post-operative period of twenty- four hours divided into two phases, the early (0-6 hrs.) and late (6-24hrs.). The frequency of nausea and vomiting, requirement of resci=ue antiemetics were studied. Nausea was evaluated according to the VAS scores. The general characteristics of the patient in the two groups were similar. In both groups, induction, maintenance, duration of anesthesia as well as the type of surgery and opioids requirement similar. The data recorded were statistically analyzed using Chi-square, t-rest. Results: The frequency of vomiting, nausea and its severity were less in ondansetron group compared to metoclopramide, but statistically these differences were not significant. The only statistically significant (p=0.03) was rescue antiemetics . Rescue antimetics was given only once in ondasnsetron group patients, whereas the need of rescue antiemetic eight times in the metoclopramide group. No unwanted effects were noticed in both groups. Conclusion: ondansetron seems more effective in preventing PONY than metoclopramide but it has to be evaluated further by more clinical trials and tests in larger series.